May 18, 2022 / 03:00PM GMT
Greg Renza - RBC Capital Markets - Senior Biotechnology Analyst
Welcome back to the 2022 RBC Global Healthcare Conference. My name is Greg Renza, one of the biotechnology equity research analysts here at RBC, and we're pleased to be joined today by Nurix therapeutics. And joining us from the Company is the CEO, Arthur Sands and the EVP of Finance business and strategy, Jason Kantor.
Gentlemen, thanks. Thanks for being here.
Arthur Sands - Nurix Therapeutics - President & CEO
Thanks for having us, Greg.
Questions and Answers:
Greg Renza - RBC Capital Markets - Senior Biotechnology AnalystIt's good to see you again and to be in person. And maybe for those who aren't as familiar with the Nurix story. Maybe you can provide us an overview, Arthur, of the company, of the portfolio.
Arthur Sands - Nurix Therapeutics - President & CEO
Sure. So, we create small molecule drugs for drug discovery company and a particular new area of medicine, which is called